Target intelligence / Profile preview

Uropathogenic Escherichia coli early biofilm formation machinery (UPEC Biofilm Machinery)

Target
UPEC Biofilm Machinery
Molecular classification
Bacterial Adhesin, Chaperone-Usher System, Extracellular Fiber, Protein Complex
01

Overview

The uropathogenic Escherichia coli (UPEC) early biofilm formation machinery is a coordinated system of surface organelles and assembly pathways essential for the initiation of urinary tract infections (UTIs). The primary component is the Type 1 pilus, which utilizes the FimH adhesin at its distal tip; FimH binds with high affinity to mannosylated uroplakins on the host bladder surface, a process that triggers bacterial invasion and the formation of protective intracellular bacterial communities (IBCs) [Spaulding et al., 2017; Sauer et al., 2019]. This machinery also includes the chaperone-usher pathway (CUP), which is responsible for the folding and transport of pilus subunits across the bacterial envelope, and curli fibers that contribute to the structural integrity of the extracellular biofilm matrix [Hultgren et al., 1993; Greene et al., 2015]. By enabling stable attachment and colonization, this machinery allows UPEC to resist the mechanical flushing of urine and evade host immune detection [Anderson et al., 2003]. Therapeutic strategies targeting this system, such as FimH antagonists (e.g., mannosides like GSK3882347) and pilicides (e.g., FN075), aim to prevent infection by blocking adhesion and assembly rather than killing the bacteria, thereby offering a potential solution to the growing challenge of antibiotic resistance in recurrent UTIs [Totsika et al., 2012; Greene et al., 2015].

Other names
UPEC adhesion machineryType 1 fimbriae assembly systemUPEC biofilm initiation complexFimH-mediated adhesion systemChaperone-usher pathway (CUP) machinery
02

Mechanism of action

The machinery is targeted primarily through the competitive inhibition of the FimH adhesin, which prevents the attachment of Type 1 pili to mannosylated uroplakins on the bladder wall [Spaulding et al., 2017]. Additionally, small-molecule pilicides and curlicides disrupt the chaperone-usher pathway (CUP) by binding to periplasmic chaperones or the outer membrane usher, thereby blocking the assembly of functional fimbriae and curli fibers required for biofilm initiation and structural stability [Greene et al., 2015].

03

Biological functions

Bacterial AdhesionBiofilm FormationHost Cell InvasionColonization
04

Disease associations

Urinary Tract InfectionCystitisPyelonephritisCatheter-Associated Urinary Tract InfectionSepsis
05

Safety considerations

Potential for off-target binding to human mannose-binding lectins (MBLs) [Spaulding et al., 2017]Challenges in maintaining therapeutic drug concentrations in the urinary tract [Flores-Mireles et al., 2015]Potential for bacteria to utilize alternative adhesion systems to bypass inhibition [Wright et al., 2007]Minimal but potential impact on the commensal gut microbiota [Spaulding et al., 2017]
06

Interacting drugs

GSK3882347

4 more in the full profile.

07

Biomarkers

FimH expression levels in clinical UPEC isolates [Wright et al., 2007]Mannose-sensitive hemagglutination (MSHA) inhibition titers [Sauer et al., 2019]Reduction in urinary bacterial load (CFU/mL) [Flores-Mireles et al., 2015]Presence of biofilm-associated matrix proteins like CsgA in urine [Greene et al., 2015]

Beyond the preview

Go deeper on Uropathogenic Escherichia coli early biofilm formation machinery (UPEC Biofilm Machinery).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uropathogenic Escherichia coli early biofilm formation machinery (UPEC Biofilm Machinery).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call